摘要
The efficacy of immunotherapy in advanced HER2-mutated non-small-cell lung cancer (NSCLC) remains incomprehensively studied. A total of 107 NSCLC patients with de novo HER2 mutations were retrospectively studied at Guangdong Lung Cancer Institute [GLCI cohort, exon 20 insertions (ex20ins): 71.0%] to compare clinical/molecular features and immune checkpoint inhibitor (ICI)-based therapy efficacy between patients with ex20ins and non-ex20ins. Two external cohorts (TCGA, n = 21; META-ICI, n = 30) were used for validation. In the GLCI cohort, 68.2% of patients displayed programmed death-ligand 1 (PD-L1) expression < 1%. Compared with ex20ins patients, non-ex20ins patients had more concurrent mutations in the GLCI cohort (P < 0.01) and a higher tumour mutation burden in the TCGA cohort (P = 0.03). Under ICI-based therapy, advanced NSCLC patients with non-ex20ins had potentially superior progression-free survival [median: 13.0 vs. 3.6 months, adjusted hazard ratio (HR): 0.31, 95% confidence interval (CI): 0.11-0.83] and overall survival (median: 27.5 vs. 8.1 months, adjusted HR: 0.39, 95% CI: 0.13-1.18) to ex20ins patients, consistent with findings in the META-ICI cohort. ICI-based therapy may serve as an option for advanced HER2-mutated NSCLC, with potentially better efficacy in non-ex20ins patients. Further investigations are warranted in clinical practice.
学科与关键词
- Efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer harboring ERBB2 exon 20 insertions and non-ERBB2 exon 20 insertionsTu, Hai-Yan; Kai Yin; Ke, E-E; Wu, Si-Pei; Zhao, Xiaotian; Li, Yang-Si; Zheng, Mei-Mei; Liu, Si-Yang Maggie; Sun, Yue-Li; Lin, Jia-Xin; Bai, Xiao-Yan; Zhang, Yi-Chen; Qing Zhou; Yang, Jin-Ji; Zhong, Wenzhao; Wang, Bin-Chao; Zhu, Dongqin; Yang, Lingling; Ou, Qiuxiang; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancerZhang, Jiexia; Zhou, Ningning; Lin, Anqi; Luo, Peng; Chen, Xin; Deng, Huojin; Kang, Shijun; Guo, Linlang*; Zhu, Weiliang*; Zhang, JianCancer Immunology, Immunotherapy, 2021, 70(1): 137-151.被引 60
- First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trialLiu, Si-Yang Maggie; Tu, Hai-Yan; Wei, Xue-Wu; Yan, Hong-Hong; Dong, Xiao-Rong; Cui, Jiu-Wei; Zhou, Zhen; Xu, Chong-Rui; Zheng, Ming-Ying; Li, Yang-Si; Wang, Zhen; Bai, Xiao-Yan; Li, An-Na; Sun, Yue-Li; Huang, Jie; Lin, Jia-Xin; Ke, E. E.; Xu, Bing-Fei; Lu, Chang; Du, Yingying; Chen, Yuan; Ma, Rui; Wang, Bu-Hai; Cang, Shun-Dong; Wang, Bin-Chao; Chen, Hua-Jun; Yang, Jin-Ji; Li, Yangqiu*; Zhou, Qing*; Wu, Yi-Long*Nature Medicine, 2023, 29(8): 2079-+.被引 5
